Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyporin N vs Restasis in Moderate to Severe Dry Eye Disease
NCT02461719Phase 3Completed
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of TJO-087 in dry eye syndrome (DED) (2 arms), sponsored by Taejoon Pharmaceutical Co., Ltd. Primary endpoint: Corneal staining test at 12 weeks. Started Jan 2014; status: completed.
02
Drugs
TJO-087
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT02461719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461719.